Dietz A, Keilholz U, Werner J, Hagen R, Flentje M, Iro H
Die Institutsangaben sind am Ende des Beitrags gelistet, Klinik und Poliklinik für HNO-Heilkunde, plastische Operationen, Universitätsklinik Leipzig, Leipzig.
Laryngorhinootologie. 2008 Apr;87(4):237-43; discussion 244. doi: 10.1055/s-2007-995588.
According to recent publications in the New England Journal of Medicine (TAX323, TAX324) of the study groups around Jan Vermorken and Marshall Posner induction chemotherapy in squamous cell carcinomas of the head-neck area (in the closer: Oro-hypopharynx, oral cavity and larynx) currently seems to generate a worldwide renaissance. Renaissance, because in the last few decades, induction chemo therapy in this group of tumors after lack of survival improvement in the vast majority of studies was again abandoned. The new data raise the question for which entities induction chemo therapy can be recommended (actually, a combination of docetaxel, cisplatin and 5-fluorouracil; TPF)? The unbroken high value of primary surgery with adjuvant radiation or chemo radiation was complementary to primary radio chemotherapy for non resectable tumors until today worldwide. Running studies are sorting out the role of induction chemotherapy in the current context of clarifying optimal multimodal treatment.
根据近期发表在《新英格兰医学杂志》（TAX323、TAX324）上的文章，扬·韦尔莫肯（Jan Vermorken）和马歇尔·波斯纳（Marshall Posner）周围的研究小组对头颈部区域鳞状细胞癌（具体为口咽下部、口腔和喉部）进行诱导化疗，目前在全球范围内似乎正在复兴。之所以说是复兴，是因为在过去几十年里，在绝大多数研究未能改善生存率之后，这类肿瘤的诱导化疗再次被放弃。新的数据引发了一个问题，即对于哪些实体瘤可以推荐使用诱导化疗（实际上是多西他赛、顺铂和5-氟尿嘧啶的联合使用；TPF）？直到如今，在全球范围内，对于不可切除的肿瘤，辅助放疗或放化疗的一期手术的持续高价值与一期放化疗相辅相成。正在进行的研究正在梳理诱导化疗在当前明确最佳多模式治疗背景下的作用。
